Uta Friederike Lessel

This inventor holds 12 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 11 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Arena Pharmaceuticals, Inc.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Uta Friederike Lessel. Retrieved from https://idiyas.com/inventor/uta-friederike-lessel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Maselheim, DE (2016 - 2023)
Ingelheim am Rhein, DE (2023)

Company Filing History:

12 out of 1,561

Boehringer Ingelheim International Gmbh

patents

1 out of 218

Arena Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497401 - Substituted tetrazoles as TRPA1 inhibitors (2025-12-16),

2. 11780827 - Substituted 3-phenoxyazetidin-1-yl-pyrazines (2023-10-10),

3. 11578080 - Thienopyrimidones (2023-02-14),

4. 11324724 - N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides (2022-05-10),

5. 11236072 - N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides (2022-02-01),

6. 10787432 - N-[(pyridyloxy)propanyl]benzamides (2020-09-29),

7. 10738031 - N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity (2020-08-11),

8. 10710984 - N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides (2020-07-14),

9. 10604511 - N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity (2020-03-31),

10. 10392369 - N-[(pyrimidinyloxy)propanyl]benzamides (2019-08-27),

11. 9884854 - N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides (2018-02-06),

12. 9233953 - Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 (2016-01-12),

Title: The Inventive Journey of Uta Friederike Lessel

Introduction:

Uta Friederike Lessel, a prolific inventor hailing from Maselheim, Germany, has left a lasting mark in the field of pharmaceutical innovations with a remarkable portfolio of 11 patents.

Latest Patents:

Lessel's latest patents showcase his expertise in developing cutting-edge pharmaceutical compounds. One notable invention includes substituted 3-phenoxyazetidin-1-yl-pyrazines, which act as agonists of GPR52, offering potential treatments for various central nervous system diseases. Additionally, his invention of thienopyrimidinones as inhibitors of TRPA1 activity demonstrates his commitment to combating fibrotic diseases, inflammatory conditions, and autoimmune disorders.

Career Highlights:

Having contributed significantly to the pharmaceutical industry, Lessel has been associated with renowned companies such as Boehringer Ingelheim International GmbH and Arena Pharmaceuticals, Inc. His expertise and dedication have propelled the development of innovative medical solutions, benefiting countless individuals worldwide.

Collaborations:

Throughout his career, Lessel has collaborated with exceptional professionals in the field. Notable coworkers include Doris Riether and Marco Ferrara, who have worked alongside him to bring forth novel pharmaceutical discoveries and advance the boundaries of medical science.

Conclusion:

Uta Friederike Lessel's inventive spirit and relentless pursuit of scientific excellence have solidified his position as a trailblazer in the realm of pharmaceutical innovations. His patents stand as a testament to his ingenuity and unwavering commitment to improving healthcare outcomes and addressing unmet medical needs.

Profile summary based on public USPTO records.